Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

2.4K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

171
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
171
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
128
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

95
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
95

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists.

Rheumatology advances in practice·2026
Same author

Care of the Patient with Interstitial Lung Disease Perioperatively.

Current rheumatology reports·2026
Same author

Necrotizing and Nonnecrotizing Granulomatous Reactions in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Literature Review.

The Journal of rheumatology·2025
Same author

Association of COVID-19 vaccinations with osteoarthritis flares: A case-crossover study.

Osteoarthritis and cartilage·2025
Same author

Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination: A Narrative Review.

Rheumatic diseases clinics of North America·2024
Same author

Progressive Dyspnea in a Woman With Tracheal Stenosis and Rheumatoid Arthritis.

Chest·2024

Related Experiment Video

Updated: Jul 7, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Pipeline Therapies for Gout.

Kevin Yip1, Genna Braverman2, Linda Yue2

  • 1Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA. kyip@wyckoffhospital.org.

Current Rheumatology Reports
|December 22, 2023
PubMed
Summary

New gout treatments aim to improve serum urate control and manage flares, especially with comorbidities. Investigational therapies include novel urate-lowering agents and anti-inflammatory drugs with improved efficacy and safety profiles.

Keywords:
GoutHyperuricemiaIL-1β inhibitorsURAT1UricosuricsXanthine oxidase inhibitors

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

240
Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

4.8K

Related Experiment Videos

Last Updated: Jul 7, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

240
Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

4.8K

Area of Science:

  • Rheumatology
  • Pharmacology
  • Internal Medicine

Background:

  • Gout management often fails to achieve target serum urate levels and control flares, particularly in patients with comorbidities.
  • Existing treatments have limitations, including renal effects and varying efficacy in impaired renal function.

Purpose of the Study:

  • To review emerging and future treatment options for short- and long-term gout management.
  • To highlight novel therapeutic strategies addressing unmet needs in gout care.

Main Methods:

  • Review of current literature on investigational gout therapies.
  • Analysis of new drug classes and mechanisms of action for gout management.

Main Results:

  • Novel urate-lowering agents like dotinurad and arhalofenate show promise, with some designed for renal impairment.
  • New xanthine oxidase inhibitors (XOIs) and simplified uricase treatments are under development.
  • Investigational treatments for gout flares include IL-1β inhibitors and dapansutrile, targeting inflammasome activation.

Conclusions:

  • Emerging gout treatments offer new mechanisms to improve efficacy, manage comorbidities, and reduce side effects.
  • Future therapies aim to simplify gout management and improve patient outcomes.